| scholarly article | Q13442814 |
| P50 | author | Eduard Vieta | Q20090640 |
| Trisha Suppes | Q97540231 | ||
| P2093 | author name string | Björn Paulsson | |
| Martin Brecher | |||
| Sherry Liu | |||
| Trial 127 Investigators | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bipolar I disorder | Q4915474 |
| P1104 | number of pages | 13 | |
| P304 | page(s) | 476-488 | |
| P577 | publication date | 2009-03-16 | |
| P1433 | published in | American Journal of Psychiatry | Q1935368 |
| P1476 | title | Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). | |
| P478 | volume | 166 |
| Q37827220 | A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder |
| Q24613657 | A critical appraisal of treatments for bipolar disorder |
| Q34260074 | A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder |
| Q34502727 | Aripiprazole as augmentation therapy in bipolar patients with current minor or subsyndromal mood symptoms |
| Q48258866 | Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). |
| Q28478032 | Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature |
| Q48793990 | Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial |
| Q37781370 | Atypical antipsychotic tolerability and switching strategies in bipolar disorder |
| Q22241210 | Bipolar Disorder: An Update |
| Q52656684 | Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. |
| Q44142664 | Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. |
| Q34809427 | Class effect of pharmacotherapy in bipolar disorder: fact or misbelief? |
| Q35831460 | Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE): a pragmatic trial of complex treatment for a complex disorder |
| Q38167386 | Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder. |
| Q38211511 | Clinical decision making in the treatment of mixed states |
| Q48448795 | Clinical implications of predominant polarity and the polarity index in bipolar disorder: a naturalistic study |
| Q34297422 | Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance |
| Q34308027 | Combination therapy for manic phases: a critical review of a common practice |
| Q34833550 | Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study |
| Q48068105 | Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial. |
| Q42972743 | Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder |
| Q28686902 | Current and emerging therapies for the management of bipolar disorders |
| Q38586755 | Diagnosis, Epidemiology and Management of Mixed States in Bipolar Disorder |
| Q52673200 | Differential effect of quetiapine and lithium on functional connectivity of the striatum in first episode mania. |
| Q28077687 | Do Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview |
| Q34197988 | Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials |
| Q44317309 | Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1-year European observational study |
| Q48063091 | Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial |
| Q48310435 | Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study |
| Q38012647 | Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry |
| Q38069670 | Eficcacy of extended release quetiapine in affective symptoms |
| Q34122946 | Emerging treatments in the management of bipolar disorder - focus on risperidone long acting injection. |
| Q46032928 | Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. |
| Q34676317 | Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology |
| Q38157027 | Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy |
| Q26824955 | Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012 |
| Q37384758 | Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort. |
| Q34515834 | LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY |
| Q34474219 | Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study |
| Q33886093 | Long-acting risperidone: a review of its role in the treatment of bipolar disorder |
| Q48910862 | Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design |
| Q37675302 | Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment |
| Q89764732 | Maintenance efficacy designs in psychiatry: Randomized discontinuation trials - enriched but not better |
| Q34268760 | Maintenance therapies in bipolar disorders |
| Q42603284 | Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials |
| Q35365539 | Management of bipolar depression |
| Q57612238 | Management of inter-episodic periods in patients with bipolar disorder |
| Q64321080 | Medication nonadherence in bipolar disorder: a narrative review |
| Q37696241 | Mixed episodes with psychotic features. |
| Q48537074 | Mood instability and functional recovery in bipolar disorders |
| Q101574247 | Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials |
| Q36069919 | Multi-state outcome analysis of treatments (MOAT): application of a new approach to evaluate outcomes in longitudinal studies of bipolar disorder |
| Q34148283 | Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder |
| Q33673618 | Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study. |
| Q37124973 | Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. |
| Q37960632 | Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review |
| Q42252223 | Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection |
| Q34349641 | Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis |
| Q36349023 | Pharmacological treatment of mixed states |
| Q48248419 | Population study of disease burden, management, and treatment of bipolar disorder in Sweden: a retrospective observational registry study |
| Q38237319 | Quetiapine extended release for the treatment of bipolar disorder |
| Q37879142 | Quetiapine monotherapy for bipolar depression |
| Q34272859 | Quetiapine: a pharmacoeconomic review of its use in bipolar disorder |
| Q37954423 | Refractoriness in bipolar disorder: definitions and evidence-based treatment |
| Q38350551 | Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review). |
| Q42733571 | Safety Assessment of Liver Injury with Quetiapine Fumarate XR Management in Very Heavy Drinking Alcohol-Dependent Patients |
| Q50719590 | Short-term quetiapine treatment alters the use of reinforcement signals during risky decision-making and promotes the choice of negative expected values in healthy adult males. |
| Q45045477 | Should the term 'antipsychotic' be changed to 'multidimensional stabiliser' in bipolar disorder? Towards a new denomination for 'atypical antipsychotics'. |
| Q34504598 | Stability of lithium treatment in bipolar disorder - long-term follow-up of 346 patients |
| Q37954416 | State of the art: treatment of bipolar disorders. |
| Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
| Q34649187 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder |
| Q35559908 | The clinical management of bipolar disorder: a review of evidence-based guidelines |
| Q34331882 | The diagnosis and treatment of bipolar disorder: decision-making in primary care |
| Q37321565 | The presentation, recognition and management of bipolar depression in primary care |
| Q38157024 | The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder |
| Q37873301 | The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder |
| Q39048607 | Treating mixed mania/hypomania: a review and synthesis of the evidence |
| Q35203680 | Treatment implications of predominant polarity and the polarity index: a comprehensive review |
| Q39287194 | Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice? |
| Q57730484 | Treatment of bipolar depression |
| Q37973144 | Treatment of mixed bipolar states |
| Q44797813 | Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? |
| Q36393992 | Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders |
| Q91599696 | What to Do When Your Depressed Patient Develops Mania |
| Q37768439 | Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults |
| Q35577365 | Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles |
| Q28281197 | The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Tria |
Search more.